Metastatic Breast Cancer
Conditions
Keywords
Post-Menopausal Patients, Hormone-Receptor Positive, Resistant to Aromatase Inhibitor Therapy, Fulvestrant, Faslodex, mTOR Inhibitor, Everolimus, RAD001, Afinitor
Brief summary
Post-menopausal women with hormone-receptor positive (HR+) metastatic breast cancer resistant to aromatase inhibitor (AI) therapy will be randomized to receive Fulvestrant (Faslodex) with Everolimus or Fulvestrant (Faslodex) with a placebo (no active ingredients). Fulvestrant has demonstrated activity when used as first, second, or third line endocrine therapy, making it an attractive therapy for combination with other agents. In addition, it is commonly reserved for use following disease progression on AI therapy. Everolimus is an orally administered drug that blocks a signaling pathway called mTOR. mTOR acts as a regulator for many processes in the body, including cell growth. Blocking this pathway may have an effect on cell growth. The combination of a novel class of agents (mTOR inhibitors) and an established standard treatment for metastatic HR+ breast cancer may potentially increase the clinical benefit by targeting multiple different biological pathways.
Detailed description
Breast cancer is the most commonly diagnosed malignancy in women worldwide. In the United States, an estimated 230,480 new cases of invasive breast cancer were diagnosed in 2011, with 39,520 breast cancer deaths. In 40-80% of women with node-positive disease at diagnosis, their breast cancer will recur. When distant metastases occur, median survival is 18 to 36 months from time of recurrence. Among the 60-70% of women with HR+ breast cancer, 40-60% of them will benefit from endocrine therapy. Endocrine therapy has shown to yield similar survival rates in hormone-sensitive disease as compared to chemotherapy; although response rates are lower and responses develop more slowly. Endocrine therapy is considerably less toxic than chemotherapy, and is therefore the preferred treatment option for patients with HR+ disease. Endocrine therapy represents the foundation of treatment for HR+ metastatic and locally advanced breast cancer. Multiple compounds in varying classes exist, and those most widely used include the selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and the selective estrogen receptor down-regulators (SERDs). Although the utility of these drugs is well established, as many as 50% of women with HR+ breast cancer will fail to respond to endocrine treatment. Moreover, those who do respond will inevitably develop acquired resistance. Fulvestrant is the first drug which acts as a pure estrogen receptor (ER) antagonist without known agonist effects. It competitively binds to the ERs with an approximately 100 times greater affinity than that of tamoxifen. Fulvestrant promotes the degradation of ERs and subsequently prevents ER-mediated gene transcription. Everolimus (RAD001) is an oral derivative of rapamycin that is an m-TOR inhibitor. At cellular and molecular levels, everolimus acts as a signal transduction inhibitor. Everolimus selectively inhibits mTOR (mammalian target of rapamycin); a key and highly conserved serine-threonine kinase which is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis and cell survival. mTOR is the only currently known target of everolimus. In oncology, everolimus has been in clinical development since 2002 for patients with various hematologic and non-hematologic malignancies as a single agent or in combination with antitumor agents, including cytotoxic chemotherapeutic agents, targeted therapies, antibodies and hormonal agents. Patients will be randomized (1:1) to receive everolimus or placebo with fulvestrant after consideration of stratification factors of performance status (0 vs. 1), measurable disease (yes vs. no), and prior chemotherapy for metastatic disease (yes vs. no). Patients will be evaluated for disease response every 12 weeks, and treated until disease progression or unacceptable toxicity or withdrawal of consent for a maximum of 12 cycles (48 weeks). Patients with no evidence of progressive disease who remain on study after completing 12 cycles are unblinded and continue to receive fulvestrant alone (if originally randomized to placebo) or in combination with everolimus (if originally randomized to everolimus) at the same dose and schedule. Patients will continue to be evaluated for disease response every 12 weeks and continue until disease progression or unacceptable toxicity.
Interventions
DRUGFulvestrant
Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles). If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
DRUGEverolimus
Everolimus 10 mg (2 tablets) daily x 12 cycles. If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
DRUGPlacebo
Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
Sponsors
Novartis
PrECOG, LLC.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent. 2. ≥18 years. 3. ECOG Performance Status 0 or 1. 4. Histologically or cytologically confirmed adenocarcinoma of the breast. 5. Stage IV disease or inoperable locally advanced disease. 6. ER and/or PR-positive disease. Tumors must be HER-2/neu negative or equivocal. 7. Aromatase Inhibitor (AI) resistant, defined as: * relapsed while receiving adjuvant therapy with an AI or, * progressive disease while receiving an AI for metastatic disease 8. Received one prior cycle of fulvestrant within 28 days of randomization are eligible. * ≥2 prior doses of fulvestrant are not eligible 9. Must be female and postmenopausal. 10. May have received ≤1 prior systemic chemotherapy regimen for metastatic disease. 11. Adequate organ function: * Whole Blood Cells (WBC) ≥3.0 x 10⁹/L, Absolute neutrophil count (ANC) ≥1.5 x 10⁹/L and platelet count ≥100 x 10⁹/L * hemoglobin ≥9 g/dL * serum bilirubin ≤1.5 X ULN (Upper Limit of Normal) * Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤2.5 X ULN (≤5 x ULN in patients with liver metastases) * serum creatinine ≤1.5 X ULN * serum albumin ≥3 g/dL * fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤2.5 x ULN. * Prothrombin time (PT) with international normalized ratio (INR) ≤1.5 12. May have measurable disease, non-measurable disease, or both. 13. Basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix within the past five years treated with curative intent. History of prior malignancy are eligible if disease-free for \>3 years.
Exclusion criteria
1. Major surgery or significant traumatic injury within 4 weeks of randomization or patients that may require major surgery during the course of the study. 2. Investigational agents within 4 weeks of randomization. 3. Anticancer treatment within 4 weeks of randomization, with the following exceptions: * Bisphosphonates or Zometa for bone metastases * a GnRH analog is permitted if the patient had progressive disease on a GnRH (Gonadotropin-Releasing Hormone) analog plus a SERM (Selective Estrogen Receptor Modulators) or an AI; the GnRH analog may continue but the SERM or AI must be discontinued. 4. Prior treatment with an mTOR inhibitor. 5. Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent ≥ 5 mg prednisone or equivalent daily. 6. Receive immunization with attenuated live vaccines within one week of randomization or during the study period. 7. Current or a prior history of brain metastases or leptomeningeal disease. Must not have rapidly progressive, life-threatening metastases. 8. Known hypersensitivity/history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus or fulvestrant. 9. Congenital or acquired immune deficiency at increased risk of infection. 10. Impairment of gastrointestinal function/disease that may significantly alter the absorption of everolimus. 11. Active, bleeding diathesis. 12. History of any condition or uncontrolled intercurrent illness that in the opinion of the local investigator might interfere with or limit the patient's ability to comply with the protocol or pose additional or unacceptable risk to the patient. 13. Severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: * Symptomatic congestive heart failure of New York Heart Association Class III or IV * Unstable angina pectoris, myocardial infarction within 6 months of randomization, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease * History of symptomatic pulmonary disease or non-malignant pulmonary disease requiring treatment. * Uncontrolled diabetes as defined by fasting serum glucose \>1.5 x ULN * Active (acute or chronic) or uncontrolled severe infections * Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh Class C). Note: Detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | Every 3 months until progression or up to 3 years | Progression-free survival documented by Physical Exam, CT Scan or MRI in post-menopausal patients with hormone-receptor positive metastatic breast cancer that is resistant to aromatase inhibitor therapy treated with fulvestrant and everolimus compared to fulvestrant alone from randomization to documented disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Benefit Rate | Every 3 months until progression or up to 3 years | Clinical benefit rate is defined as number of patients with objective response (complete response or partial response) or stable disease for at least 24 weeks divided by number of patients randomized in each arm. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease; Complete Response (CR) is defined as disappearance of all target lesions. |
| Objective Response Rate | Every 3 months until progression or up to 3 years | Objective response rate is defined as number of patients with complete or partial response (by Physical Exam, CT or MRI) divided by number of patients randomized in each arm |
| Overall Survival | Every 3 months until progression or up to 3 years | Overall survival will be characterized using Kaplan-Meier plots and other descriptive metrics. |
Countries
United States
Participant flow
Recruitment details
A total of 131 patients were enrolled from 23 institutions between May 2013 and November 2015.
Participants by arm
| Arm | Count |
|---|---|
| Fulvestrant & Everolimus Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
Everolimus: Everolimus 10 mg (2 tablets) daily x 12 cycles.
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity. | 66 |
| Fulvestrant & Placebo Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
Fulvestrant: Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity.
Placebo: Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet. | 65 |
| Total | 131 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 13 | 5 |
| Overall Study | Disesae progression | 37 | 49 |
| Overall Study | never start protocol therapy | 2 | 0 |
| Overall Study | Non-compliance | 1 | 0 |
| Overall Study | Physician Decision | 3 | 0 |
| Overall Study | still on treatment | 2 | 4 |
| Overall Study | Symptomatic progression | 2 | 1 |
| Overall Study | Withdrawal by Subject | 6 | 6 |
Baseline characteristics
| Characteristic | Fulvestrant & Placebo | Total | Fulvestrant & Everolimus |
|---|---|---|---|
| Age, Continuous | 59 years | 63 years | 64 years |
| Race/Ethnicity, Customized Black | 11 Participants | 19 Participants | 8 Participants |
| Race/Ethnicity, Customized Others | 5 Participants | 7 Participants | 2 Participants |
| Race/Ethnicity, Customized White | 49 Participants | 105 Participants | 56 Participants |
| Sex: Female, Male Female | 65 Participants | 131 Participants | 66 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 30 / 66 | 21 / 65 |
| other Total, other adverse events | 59 / 64 | 38 / 65 |
| serious Total, serious adverse events | 31 / 64 | 5 / 65 |
Outcome results
Primary
Progression-free Survival
Progression-free survival documented by Physical Exam, CT Scan or MRI in post-menopausal patients with hormone-receptor positive metastatic breast cancer that is resistant to aromatase inhibitor therapy treated with fulvestrant and everolimus compared to fulvestrant alone from randomization to documented disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Every 3 months until progression or up to 3 years
Population: all randomized patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fulvestrant & Everolimus | Progression-free Survival | 10.3 months |
| Fulvestrant & Placebo | Progression-free Survival | 5.1 months |
p-value: 0.0295% CI: [0.4, 0.92]Log Rank
Secondary
Clinical Benefit Rate
Clinical benefit rate is defined as number of patients with objective response (complete response or partial response) or stable disease for at least 24 weeks divided by number of patients randomized in each arm. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR) is defined as \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease; Complete Response (CR) is defined as disappearance of all target lesions.
Time frame: Every 3 months until progression or up to 3 years
Population: all randomized patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fulvestrant & Everolimus | Clinical Benefit Rate | 0.636 proportion of patients |
| Fulvestrant & Placebo | Clinical Benefit Rate | 0.415 proportion of patients |
p-value: 0.01Fisher Exact
Secondary
Objective Response Rate
Objective response rate is defined as number of patients with complete or partial response (by Physical Exam, CT or MRI) divided by number of patients randomized in each arm
Time frame: Every 3 months until progression or up to 3 years
Population: all randomized patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Fulvestrant & Everolimus | Objective Response Rate | 0.182 proportion of patients |
| Fulvestrant & Placebo | Objective Response Rate | 0.123 proportion of patients |
p-value: 0.47Fisher Exact
Secondary
Overall Survival
Overall survival will be characterized using Kaplan-Meier plots and other descriptive metrics.
Time frame: Every 3 months until progression or up to 3 years
Population: all randomized patients
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Fulvestrant & Everolimus | Overall Survival | 28.3 months |
| Fulvestrant & Placebo | Overall Survival | 31.4 months |